@article{c15dd49d7bcc4afbbd33dc0b010d7e16,
title = "Interleukin-6 in idiopathic multicentric Castleman{\textquoteright}s disease after long-term tocilizumab",
author = "Mitsuhiro Akiyama and Hidekata Yasuoka and Tsutomu Takeuchi",
note = "Funding Information: Conflict of interest MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than \$10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than \$10,000 each). Funding Information: We thank Mrs. Keiko Yoshimoto for the assistance of data collection. This study was approved by the institutional ethics committee of Keio University School of Medicine. Informed consent was obtained from all the patients and healthy donors. MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than \$10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than \$10,000 each).",
year = "2017",
month = dec,
day = "1",
doi = "10.1007/s00277-017-3111-x",
language = "English",
volume = "96",
pages = "2117--2119",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",
}